Aqilion finalizes the eosinophilic esophagitis specific formulation pharmacokinetic study with the drug candidate AQ280
Aqilion AB is pleased to announce the completion of its second Phase 1 clinical study (ARIA-2) in the United States, as part of the AQ280 development program. The ARIA-2 study evaluated the pharmacokinetic profile of a novel, water-dissolvable tablet formulation of AQ280, designed for the treatment of eosinophilic esophagitis (EoE). The final participant has completed the study, and results are expected in October.
EoE patients have difficulties swallowing and oral therapies need to be adapted to facilitate their drug intake. Aqilion have developed a formulation that allows the EoE patients to drink the medicine like water.
The primary objective of ARIA-2 was to determine whether the new formulation exhibits a pharmacokinetic profile comparable to the capsule used in the initial Phase 1 study (ARIA-1). The study was conducted in June with healthy participants in the USA and the results are expected in October. Thereafter Aqilion plans to initiate a Phase 2 (a and b) clinical trials in patients diagnosed with EoE across the US, Canada, and Europe.
Sarah Fredriksson, CEO of Aqilion, stated, “We have completed the clinical part of the pharmacokinetic study with our new AQ280 formulation, which is an important milestone. Developing a formulation tailored for patients with difficulty swallowing is strategically extremely important. We thank the participants and clinic involved and look forward to advancing AQ280’s clinical development.”
For more information, please contact:
Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com